Gomez J
Am Heart J Plus. 2024; 17:100144.
PMID: 38559889
PMC: 10978313.
DOI: 10.1016/j.ahjo.2022.100144.
Kreidieh F, McQuade J
Am Heart J Plus. 2024; 40:100374.
PMID: 38510501
PMC: 10946000.
DOI: 10.1016/j.ahjo.2024.100374.
de Jesus M, Chanda A, Grabauskas T, Kumar M, Kim A
Front Oncol. 2024; 14:1258991.
PMID: 38410099
PMC: 10896114.
DOI: 10.3389/fonc.2024.1258991.
Inno A, Veccia A, Madonia G, Berti A, Bortolotti R, Incorvaia L
Front Cardiovasc Med. 2024; 11:1309100.
PMID: 38370161
PMC: 10869562.
DOI: 10.3389/fcvm.2024.1309100.
Butel-Simoes L, Haw T, Williams T, Sritharan S, Gadre P, Herrmann S
Hypertension. 2023; 80(4):685-710.
PMID: 36756872
PMC: 10023512.
DOI: 10.1161/HYPERTENSIONAHA.122.17947.
Cancer Immunotherapy Beyond Checkpoint Blockade: State-of-the-Art Review.
Welty N, Gill S
JACC CardioOncol. 2023; 4(5):563-578.
PMID: 36636439
PMC: 9830230.
DOI: 10.1016/j.jaccao.2022.11.006.
Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer.
Karlstaedt A, Moslehi J, de Boer R
Nat Rev Cardiol. 2022; 19(6):414-425.
PMID: 35440740
PMC: 10112835.
DOI: 10.1038/s41569-022-00698-6.
Incidence and Risk of Hypertension in Cancer Patients Treated With Atezolizumab and Bevacizumab: A Systematic Review and Meta-Analysis.
Jiang L, Tan X, Li J, Li Y
Front Oncol. 2021; 11:726008.
PMID: 34712609
PMC: 8546244.
DOI: 10.3389/fonc.2021.726008.
Severe Cardiac Toxicity Induced by Cancer Therapies Requiring Intensive Care Unit Admission.
Montisci A, Palmieri V, Liu J, Vietri M, Cirri S, Donatelli F
Front Cardiovasc Med. 2021; 8:713694.
PMID: 34540917
PMC: 8446380.
DOI: 10.3389/fcvm.2021.713694.
Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer.
Chitturi K, Xu J, Araujo-Gutierrez R, Bhimaraj A, Guha A, Hussain I
JACC CardioOncol. 2021; 1(2):182-192.
PMID: 34396181
PMC: 8352266.
DOI: 10.1016/j.jaccao.2019.11.013.
Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab.
Makker V, Taylor M, Oaknin A, Casado Herraez A, Orlowski R, Dutta L
Oncologist. 2021; 26(9):e1599-e1608.
PMID: 34190370
PMC: 8417842.
DOI: 10.1002/onco.13883.
Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors.
Fleming M, Xiao L, Jackson K, Beckman J, Barac A, Moslehi J
Circ Res. 2021; 128(12):1973-1987.
PMID: 34110908
PMC: 10185355.
DOI: 10.1161/CIRCRESAHA.121.318259.
Symptomatic Sinus Bradycardia in a Patient with Solitary Fibrous Tumor/Hemangiopericytoma Treated with Pazopanib.
Shioyama W, Oka T, Kamada R, Yagi T, Nakanishi K, Nishikawa T
Intern Med. 2021; 60(18):2973-2977.
PMID: 33814488
PMC: 8502657.
DOI: 10.2169/internalmedicine.5347-20.
Hypertension in cancer patients treated with anti-angiogenic based regimens.
Wasserstrum Y, Kornowski R, Raanani P, Leader A, Pasvolsky O, Iakobishvili Z
Cardiooncology. 2021; 1(1):6.
PMID: 33530150
PMC: 7837153.
DOI: 10.1186/s40959-015-0009-4.
Drug-Related Hypertension Associated with the Efficacy of Apatinib on Hepatocellular Carcinoma.
Yang X, Hou Z, Zhu K, Zhang S, Gu X, Wang Z
Cancer Manag Res. 2020; 12:3163-3173.
PMID: 32440214
PMC: 7212781.
DOI: 10.2147/CMAR.S240394.
Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors: A Scientific Statement From the American Heart Association.
Gilchrist S, Barac A, Ades P, Alfano C, Franklin B, Jones L
Circulation. 2019; 139(21):e997-e1012.
PMID: 30955352
PMC: 7603804.
DOI: 10.1161/CIR.0000000000000679.
Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association.
Campia U, Moslehi J, Amiri-Kordestani L, Barac A, Beckman J, Chism D
Circulation. 2019; 139(13):e579-e602.
PMID: 30786722
PMC: 6530491.
DOI: 10.1161/CIR.0000000000000641.
Cardiotoxicity with vascular endothelial growth factor inhibitor therapy.
Touyz R, Herrmann J
NPJ Precis Oncol. 2018; 2:13.
PMID: 30202791
PMC: 5988734.
DOI: 10.1038/s41698-018-0056-z.
Tyrosine Kinase Inhibitor-Induced Hypertension.
Agarwal M, Thareja N, Benjamin M, Akhondi A, Mitchell G
Curr Oncol Rep. 2018; 20(8):65.
PMID: 29931399
DOI: 10.1007/s11912-018-0708-8.
Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective.
Varricchi G, Ameri P, Cadeddu C, Ghigo A, Madonna R, Marone G
Front Physiol. 2018; 9:167.
PMID: 29563880
PMC: 5846016.
DOI: 10.3389/fphys.2018.00167.
